PRD004
Dyslipidemia
DiscoveryActive
Key Facts
About PRD Therapeutics
A biotech startup developing the world's first selective SOAT2 inhibitor oral drugs for rare and common lipid metabolism disorders.
View full company profileTherapeutic Areas
Other Dyslipidemia Drugs
| Drug | Company | Phase |
|---|---|---|
| LIVALO (pitavastatin) | Kowa Pharmaceuticals | Approved |